Summer 1969

Massachusetts Turf and Lawn Grass Council Better Turf Through Research and Education Contents: New Lawn Seeds Ready to Sprout Profits by Robert W. Schery (page 3) Potash Experiments on Turf Grasses by Edward G. Konieczny (4) Understanding the Basis... Fertilizer Spreader: Spreading Relationships (9) TVA Shows Sulpher Coated Urea (13) Salinity Tolerance of Turfgrass by Jeff Wheeler (19) Poa Annua by William H. Daniel (23) Turf Management by Elwin E. Deal (26) The Art and Science of Greenskeeping by James W. Timmerman (27

Don’t Underestimate the Benefits of Being Misunderstood

Being a nonnative speaker of a language poses challenges. Individuals often feel embarrassed by the errors they make when talking in their second language. However, here we report an advantage of being a nonnative speaker: Native speakers give foreign-accented speakers the benefit of the doubt when interpreting their utterances; as a result, apparently implausible utterances are more likely to be interpreted in a plausible way when delivered in a foreign than in a native accent. Across three replicated experiments, we demonstrated that native English speakers are more likely to interpret implausible utterances, such as “the mother gave the candle the daughter,” as similar plausible utterances (“the mother gave the candle to the daughter”) when the speaker has a foreign accent. This result follows from the general model of language interpretation in a noisy channel, under the hypothesis that listeners assume a higher error rate in foreign-accented than in nonaccented speech.National Science Foundation (U.S.) (Award 1534318

Automorphism groups of circulant digraphs with applications to semigroup theory

We characterize the automorphism groups of circulant digraphs whose connection sets are relatively small, and of unit circulant digraphs. For each class, we either explicitly determine the automorphism group or we show that the graph is a "normal" circulant, so the automorphism group is contained in the normalizer of a cycle. Then we use these characterizations to prove results on the automorphisms of the endomorphism monoids of those digraphs. The paper ends with a list of open problems on graphs, number theory, groups and semigroups

Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI) : a phase 3, placebo-controlled, randomised trial

Background: Patients with stable coronary artery disease and diabetes with previous percutaneous coronary intervention (PCI), particularly those with previous stenting, are at high risk of ischaemic events. These patients are generally treated with aspirin. In this trial, we aimed to investigate if these patients would benefit from treatment with aspirin plus ticagrelor. Methods: The Effect of Ticagrelor on Health Outcomes in diabEtes Mellitus patients Intervention Study (THEMIS) was a phase 3 randomised, double-blinded, placebo-controlled trial, done in 1315 sites in 42 countries. Patients were eligible if 50 years or older, with type 2 diabetes, receiving anti-hyperglycaemic drugs for at least 6 months, with stable coronary artery disease, and one of three other mutually non-exclusive criteria: a history of previous PCI or of coronary artery bypass grafting, or documentation of angiographic stenosis of 50% or more in at least one coronary artery. Eligible patients were randomly assigned (1:1) to either ticagrelor or placebo, by use of an interactive voice-response or web-response system. The THEMIS-PCI trial comprised a prespecified subgroup of patients with previous PCI. The primary efficacy outcome was a composite of cardiovascular death, myocardial infarction, or stroke (measured in the intention-to-treat population). Findings: Between Feb 17, 2014, and May 24, 2016, 11 154 patients (58% of the overall THEMIS trial) with a history of previous PCI were enrolled in the THEMIS-PCI trial. Median follow-up was 3·3 years (IQR 2·8–3·8). In the previous PCI group, fewer patients receiving ticagrelor had a primary efficacy outcome event than in the placebo group (404 [7·3%] of 5558 vs 480 [8·6%] of 5596; HR 0·85 [95% CI 0·74–0·97], p=0·013). The same effect was not observed in patients without PCI (p=0·76, p interaction=0·16). The proportion of patients with cardiovascular death was similar in both treatment groups (174 [3·1%] with ticagrelor vs 183 (3·3%) with placebo; HR 0·96 [95% CI 0·78–1·18], p=0·68), as well as all-cause death (282 [5·1%] vs 323 [5·8%]; 0·88 [0·75–1·03], p=0·11). TIMI major bleeding occurred in 111 (2·0%) of 5536 patients receiving ticagrelor and 62 (1·1%) of 5564 patients receiving placebo (HR 2·03 [95% CI 1·48–2·76], p<0·0001), and fatal bleeding in 6 (0·1%) of 5536 patients with ticagrelor and 6 (0·1%) of 5564 with placebo (1·13 [0·36–3·50], p=0·83). Intracranial haemorrhage occurred in 33 (0·6%) and 31 (0·6%) patients (1·21 [0·74–1·97], p=0·45). Ticagrelor improved net clinical benefit: 519/5558 (9·3%) versus 617/5596 (11·0%), HR=0·85, 95% CI 0·75–0·95, p=0·005, in contrast to patients without PCI where it did not, p interaction=0·012. Benefit was present irrespective of time from most recent PCI. Interpretation: In patients with diabetes, stable coronary artery disease, and previous PCI, ticagrelor added to aspirin reduced cardiovascular death, myocardial infarction, and stroke, although with increased major bleeding. In that large, easily identified population, ticagrelor provided a favourable net clinical benefit (more than in patients without history of PCI). This effect shows that long-term therapy with ticagrelor in addition to aspirin should be considered in patients with diabetes and a history of PCI who have tolerated antiplatelet therapy, have high ischaemic risk, and low bleeding risk